Company profile
Oric Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ORIC-101 | phase1 | — | 4 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07723248 | phase3 | recruiting | 2026-08-03 | 2028-03-01 | ORIC Pharmaceuticals | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) |
| NCT06012721 | phase1 | completed | 2023-09-11 | 2023-11-23 | ORIC Pharmaceuticals | Effect of Food on the Pharmacokinetics of ORIC-114 |
| NCT06816992 | phase1 | recruiting | 2025-02-27 | 2026-12-01 | ORIC Pharmaceuticals | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC |
| NCT03835637 | phase1 | completed | 2018-03-23 | 2018-07-04 | ORIC Pharmaceuticals | Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects |
| NCT03928314 | phase1 | terminated | 2019-05-02 | 2022-09-22 | ORIC Pharmaceuticals | Study of ORIC-101 in Combination With Anticancer Therapy |
FDA applications (0)
No records yet.